Aequs shares plunged nearly 19% on October 27, 2026, after the aerospace and precision-manufacturing company reported a sharp deterioration in profitability for the second quarter of FY27. Revenue from operations rose 45.3% year over year to ₹409.1 crore, but its consolidated net loss widened to ₹52.4 crore from ₹20.6 crore a year earlier. EBITDA fell 45% to approximately ₹24.5 crore, while the EBITDA margin contracted to 6% from 16%.
The results exposed a growing gap between Aequs’ strong aerospace demand and its overall financial performance. Its consumer business is struggling with slower production ramp-ups and low factory utilisation, prompting management to reassess the timeline for achieving break-even. Although the company has an aerospace order book worth approximately $1.1 billion, investors are concerned about rising costs, delayed profitability and the capital required to support future expansion.
Key Takeaways
- Stock decline: Aequs shares fell nearly 19% on October 27 following its Q2 FY27 results.
- Revenue growth: Revenue from operations increased 45.3% year over year to ₹409.1 crore.
- Widening losses: Consolidated net loss increased to ₹52.4 crore from ₹20.6 crore in Q2 FY26.
- Margin pressure: EBITDA declined 45% to approximately ₹24.5 crore, reducing the margin to 6% from 16%.
- Consumer business weakness: Revenue and capacity utilisation disappointed, while the break-even timeline is being recalibrated.
- Aerospace opportunity: The order book stood at approximately $1.1 billion, but converting orders into profitable growth remains critical.
Aequs Q2 FY27 Results: Revenue Growth Fails to Impress Investors
Aequs released its September-quarter results after market hours on October 26. The company reported strong year-over-year revenue growth, but operating profitability weakened significantly.
Q2 FY27 financial performance
| Financial metric | Q2 FY27 | Q2 FY26 | Year-over-year change |
|---|---|---|---|
| Revenue from operations | ₹409.1 crore | ₹281.6 crore | +45.3% |
| Consolidated net loss | ₹52.4 crore | ₹20.6 crore | Loss widened |
| EBITDA | ₹24.5 crore | ₹44.5 crore | -45% |
| EBITDA margin | 6% | 16% | -10 percentage points |
Figures are rounded. Source: The Economic Times and Inc42.
The results demonstrate why revenue growth alone did not reassure investors. A company can increase sales without improving its bottom line if manufacturing costs, employee expenses, depreciation, interest and other operating expenses rise faster than revenue.
For Aequs, the sharp decline in EBITDA suggests that the additional revenue generated during the quarter did not translate into comparable operating earnings. The widening net loss added to concerns about how quickly the business can move towards sustainable profitability.
Why Did Aequs Shares Fall Nearly 19%?
1. Consumer business losses are weighing on profitability
The consumer business has become a major source of concern for investors. The segment manufactures products and components for categories such as consumer electronics and other consumer goods, but its financial performance depends on increasing production volumes and making better use of manufacturing capacity.
According to brokerage commentary reported by The Economic Times, the consumer segment’s loss widened to approximately ₹40 crore, while revenue declined 21% sequentially. Capacity utilisation also fell to 17% from 22% in Q1 FY27, indicating that a relatively small proportion of installed capacity was being used.
Aequs attributed the slower ramp-up to extended customer qualification timelines and supply-chain constraints. Management described the delays as timing-related rather than a deterioration in the underlying opportunity.
Nevertheless, low utilisation can make manufacturing expensive because fixed costs must be spread across fewer units. Until production volumes improve, the consumer business could continue to absorb cash and offset gains from aerospace.
2. The break-even timeline has become uncertain
Investors had expected the consumer business to progress towards EBITDA break-even. The slower production ramp-up has forced Aequs to recalibrate that path, with no firm revised timeline highlighted in the brokerage commentary.
This uncertainty matters because profitability forecasts often depend on assumptions about when new facilities will reach sufficient utilisation. If the ramp-up takes longer than expected, the company may continue recording losses even as revenue increases.
The longer the delay, the more important it becomes for Aequs to manage working capital, operating expenses and investment commitments. Investors will likely look for measurable improvements in utilisation and segment earnings before placing greater confidence in a recovery.
3. EBITDA fell much faster than revenue grew
Aequs’ revenue increased 45.3% year over year, but EBITDA declined 45%. The contrast points to significant pressure on operating profitability.
EBITDA measures earnings before interest, taxes, depreciation and amortisation. It helps investors assess how a business performs before financing costs and certain accounting expenses.
The fall in EBITDA margin from 16% to 6% means Aequs generated substantially less operating earnings from each rupee of sales than it did a year earlier. That deterioration can affect the company’s ability to fund expansion, absorb unexpected costs and eventually report net profits.
Aerospace Business Remains Aequs’ Biggest Strength
Despite the disappointing consolidated results, Aequs’ aerospace business continued to grow strongly.
| Aerospace metric | Q2 FY27 performance |
|---|---|
| Segment revenue | ₹351.4 crore |
| Year-over-year revenue growth | 44.2% |
| Share of consolidated operating revenue | Approximately 85.9% |
| Aerospace order book | Approximately $1.1 billion |
Source: Inc42 and The Economic Times.
The aerospace division supplies precision-engineered components for aircraft programmes and benefits from demand for specialised manufacturing capabilities. Its order book provides potential revenue visibility over several years, although orders do not automatically translate into immediate sales or profits.
Aequs is also expanding its aerospace relationships and production capabilities. The company has signed a long-term supply agreement with Safran and is developing its aerospace manufacturing presence at Hosur.
These initiatives could strengthen the business over time. However, new capacity requires investment and may generate depreciation and other costs before reaching full production. The pace at which new facilities become commercially productive will therefore matter to earnings.
What Brokerages Are Saying About Aequs Stock
Brokerage reactions highlighted the difference between Aequs’ long-term aerospace prospects and its near-term earnings challenges.
| Brokerage | Reported rating | Target price | Main concern or rationale |
|---|---|---|---|
| Nuvama Institutional Equities | Buy | ₹444 | Strong aerospace franchise and order book, despite consumer losses |
| JM Financial | Reduce | ₹245 | Weak consumer sales and utilisation, lower EBITDA and delayed break-even |
Source: The Economic Times.
The different recommendations underline the uncertainty surrounding the stock. Nuvama maintained a positive view based on the aerospace business and promoter investment, while JM Financial retained a Reduce rating despite raising its target price.
These are brokerage estimates, not guaranteed outcomes. Target prices can change as new results, business conditions and valuation assumptions emerge.
What Investors Should Watch Next
Several indicators could help investors assess whether Aequs is moving towards a recovery:
- Consumer capacity utilisation: A sustained improvement would indicate that recently installed capacity is generating more production.
- Consumer EBITDA losses: Investors will want to see the segment’s losses narrow consistently rather than relying solely on revenue growth.
- Consolidated EBITDA margin: A recovery from the 6% level would indicate improving operating economics.
- Aerospace order conversion: The company needs to turn its order book into production, revenue and cash generation.
- Capital expenditure and financing: Expansion plans must be balanced against the cost of building capacity and the cash required to support operations.
The next few quarters should help clarify whether the consumer business is experiencing temporary ramp-up delays or a more persistent profitability problem.
The Bigger Picture
Aequs’ Q2 FY27 results illustrate the risks of investing in a fast-growing manufacturing company before its earnings fully reflect that growth. Aerospace demand and a large order book can provide a strong foundation, but investors ultimately need evidence that sales growth is translating into sustainable operating profits and cash generation.
The company now faces the task of improving consumer utilisation while expanding its aerospace capabilities without allowing fixed costs and financing needs to overwhelm earnings. Its long-term prospects will depend on execution, not just demand. Until profitability improves, the stock may remain sensitive to quarterly results and changes in management’s guidance.
FAQs
1. Why did Aequs shares fall nearly 19%?
Aequs shares fell after its Q2 FY27 results showed a wider consolidated net loss, a 45% decline in EBITDA and a contraction in EBITDA margin to 6%. Investors were also concerned about losses and delayed break-even in the consumer business.
2. What was Aequs’ Q2 FY27 net loss?
Aequs reported a consolidated net loss of approximately ₹52.4 crore, compared with ₹20.6 crore in Q2 FY26.
3. Did Aequs revenue decline in Q2 FY27?
No. Revenue from operations rose 45.3% year over year to approximately ₹409.1 crore. However, EBITDA fell and the net loss widened, showing that higher sales did not translate into improved overall profitability.
4. Is Aequs’ aerospace business performing well?
The aerospace segment reported revenue of approximately ₹351.4 crore, up 44.2% year over year. Its order book was around $1.1 billion, although the company still needs to convert those orders into profitable production and revenue.
5. Should investors buy Aequs shares after the fall?
A sharp price decline alone does not establish that a stock is undervalued. Investors should assess the company’s valuation, cash needs, segment performance, profitability outlook and risk tolerance. Brokerage views differ, and their target prices are not guarantees of future returns.
Looking Ahead
Aequs’ near-term performance will depend heavily on whether the consumer business can improve utilisation and reduce losses while the aerospace division continues to grow. Investors will also watch for clearer guidance on break-even, margins and the financial implications of the company’s expansion plans.
The $1.1 billion aerospace order book offers a potential source of long-term growth, but the market’s reaction shows that investors want evidence of earnings delivery alongside revenue growth. Until margins recover and the path to consolidated profitability becomes clearer, Aequs is likely to remain a closely watched but execution-sensitive manufacturing stock.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
